KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Shares Issued (2017 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Shares Issued for 16 consecutive years, with $41.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Issued rose 14.95% year-over-year to $41.7 million, compared with a TTM value of $250.0 million through Dec 2025, down 17.47%, and an annual FY2025 reading of $250.0 million, down 17.47% over the prior year.
  • Shares Issued was $41.7 million for Q4 2025 at Alnylam Pharmaceuticals, down from $77.7 million in the prior quarter.
  • Across five years, Shares Issued topped out at $153.0 million in Q3 2022 and bottomed at $22.5 million in Q2 2022.
  • Average Shares Issued over 5 years is $60.3 million, with a median of $48.2 million recorded in 2021.
  • The sharpest move saw Shares Issued crashed 83.79% in 2023, then surged 335.54% in 2024.
  • Year by year, Shares Issued stood at $45.0 million in 2021, then increased by 25.92% to $56.7 million in 2022, then crashed by 45.53% to $30.9 million in 2023, then rose by 17.43% to $36.3 million in 2024, then grew by 14.95% to $41.7 million in 2025.
  • Business Quant data shows Shares Issued for ALNY at $41.7 million in Q4 2025, $77.7 million in Q3 2025, and $81.2 million in Q2 2025.